The appointment of the anti-vax Kennedy jr as US healthcare sinks the inventory markets on Pharma shares | EUROtoday

Listen to the audio model of the article

The inventory markets of the pharmaceutical sector are all within the crimson, following the nomination of Robert F. Kennedy jr as the longer term Minister of Health within the United States. Known for his positions towards vaccines and anti-Covid restrictions, he is without doubt one of the most controversial appointments amongst these introduced by Tycoon, who on X mentioned: «For too lengthy, Americans have been crushed by the agribusiness complicated and from pharmaceutical corporations which have engaged in deception, misinformation and public well being disinformation”, declaring themselves “enthusiastic” about the appointment of Kennedy Jr., who will lead a Department that can count on a budget of over 1.7 trillion dollars, with a strong influence on drug regulation and public health in general.

Kennedy’s nomination also left a heavy mark on Wall Street, where, at mid-day, Pfizer was losing 4.5%, Eli Lilly 3.7% and Moderna 7.9 percent.
Effects also in Europe, where the stock exchanges have concluded trading. In Paris, Sanofi-Aventis closed at -3.2%, Valneva at -6% and Sartorius Stedim at -6.7 percent. Same picture in London, where GSK closed the week at -3.8% and Astrazeneca at -3.2 percent. In Copenhagen Novo Nordisk lost 5.3% and Zealand Pharma left over 10.1 percent on the ground. While Bavarian Nordic fell disastrously to close at -17.4%, also due to a quarterly result below expectations. Danish biotech Bavarian Nordic said its order backlog for delivery of its smallpox and smallpox vaccine in 2025 currently stands at approximately $340 million, including previously announced deferred revenue. But its CEO Paul Chaplin also underlined that «A US Health Secretary who is skeptical about vaccines does not help convince the public to take vaccines: we just have to wait and see». However, when it comes to biodefense, preparedness and response to potential pandemics, Chaplin expects the Trump administration to increase funding, as happened during his first term. Swedish Orphan Biovitrum sinks in Stockholm (-10.1 percent). The reaction of the Italian companies in the sector was decidedly more contained, with Recordati down 1.6% while Diasorin, bucking the trend, closed in positive territory at +2 percent.